Decisive point for gensight in the short termSolid'action which is about to exceed probably € 10 in the short term if we go above € 9.35 at 11:45 am.
Next report date
September 19
Report period
H1 2025
EPS estimate
—
Revenue estimate
—
−0.1513 USD
−14.49 M USD
1.55 M USD
105.46 M
About GENSIGHT BIOLOGICS
Sector
Industry
CEO
Laurence Rodriguez
Website
Headquarters
Paris
Founded
2012
ISIN
FR0013183985
FIGI
BBG00J6GYH38
GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. It also focuses on central nervous system diseases. The company was founded by Bernard Jacques Alex Gilly, Botond Roska, Jean Bennett, Connie Cepko, Luk H. Vandenberghe, Serge Picaud and Jose-Alain Sahel in 2012 and is headquartered in Paris, France.
−2,150.00%
−1,700.00%
−1,250.00%
−800.00%
−350.00%
H1 '22
H1 '23
H2 '23
H1 '24
H2 '24
−18.00 M
−12.00 M
−6.00 M
0.00
6.00 M
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
−10.50 M
−7.00 M
−3.50 M
0.00
3.50 M
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
−9.00 M
−6.00 M
−3.00 M
0.00
3.00 M
H1 '22
H1 '23
H2 '23
H1 '24
H2 '24
−26.00 M
−13.00 M
0.00
13.00 M
26.00 M
Debt
Free cash flow
Cash & equivalents
No news here
Looks like there's nothing to report right now
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GSGTF is 0.2400 USD — it has decreased by −25.00% in the past 24 hours. Watch GENSIGHT BIOLOGICS SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange GENSIGHT BIOLOGICS SA stocks are traded under the ticker GSGTF.
We've gathered analysts' opinions on GENSIGHT BIOLOGICS SA future price: according to them, GSGTF price has a max estimate of 0.39 USD and a min estimate of 0.39 USD. Watch GSGTF chart and read a more detailed GENSIGHT BIOLOGICS SA stock forecast: see what analysts think of GENSIGHT BIOLOGICS SA and suggest that you do with its stocks.
GSGTF reached its all-time high on May 6, 2021 with the price of 11.3000 USD, and its all-time low was 0.0003 USD and was reached on Oct 4, 2023. View more price dynamics on GSGTF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GSGTF stock is 33.33% volatile and has beta coefficient of 0.85. Track GENSIGHT BIOLOGICS SA stock price on the chart and check out the list of the most volatile stocks — is GENSIGHT BIOLOGICS SA there?
Today GENSIGHT BIOLOGICS SA has the market capitalization of 30.23 M, it has decreased by −0.16% over the last week.
Yes, you can track GENSIGHT BIOLOGICS SA financials in yearly and quarterly reports right on TradingView.
GENSIGHT BIOLOGICS SA is going to release the next earnings report on Sep 19, 2025. Keep track of upcoming events with our Earnings Calendar.
GSGTF net income for the last half-year is −8.44 M USD, while the previous report showed −6.26 M USD of net income which accounts for −34.74% change. Track more GENSIGHT BIOLOGICS SA financial stats to get the full picture.
No, GSGTF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 15, 2025, the company has 12 employees. See our rating of the largest employees — is GENSIGHT BIOLOGICS SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENSIGHT BIOLOGICS SA EBITDA is −16.31 M USD, and current EBITDA margin is −1.05 K%. See more stats in GENSIGHT BIOLOGICS SA financial statements.
Like other stocks, GSGTF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENSIGHT BIOLOGICS SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENSIGHT BIOLOGICS SA technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENSIGHT BIOLOGICS SA stock shows the strong sell signal. See more of GENSIGHT BIOLOGICS SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.